Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$39.01M-$39.01MN/M vs Q1 2020 EPS Diluted-$3.57-$3.57N/M vs Q1 2020 Operating Income-$5,186,000N/M Operating Cash Flow-$5,812,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 7, 2021 · 37 d after period end